Immunogenicity and Reactogenicity of 2009 Influenza A (H1N1) Inactivated Monovalent Non-Adjuvanted Vaccine in Elderly and Immunocompromised Patients

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMIRAGLIA, Joao L.
dc.contributor.authorABDALA, Edson
dc.contributor.authorHOFF, Paulo M.
dc.contributor.authorLUIZ, Andre M.
dc.contributor.authorOLIVEIRA, Danise S.
dc.contributor.authorSAAD, Carla G. S.
dc.contributor.authorLAURINDO, Ieda M. M.
dc.contributor.authorVISO, Ana T. R.
dc.contributor.authorTAYRA, Angela
dc.contributor.authorPIERROTTI, Ligia C.
dc.contributor.authorAZEVEDO, Luiz S.
dc.contributor.authorCAMPOS, Lucia Maria A.
dc.contributor.authorAIKAWA, Nadia E.
dc.contributor.authorTIMENETSKY, Maria do Carmo S. T.
dc.contributor.authorLUNA, Expedito
dc.contributor.authorCARDOSO, Maria Regina A.
dc.contributor.authorGUEDES, Jose da S.
dc.contributor.authorRAW, Isaias
dc.contributor.authorKALIL, Jorge
dc.contributor.authorPRECIOSO, Alexander R.
dc.date.accessioned2017-11-27T16:25:45Z
dc.date.available2017-11-27T16:25:45Z
dc.date.issued2011
dc.description.abstractBackground: Immunosuppressed individuals present serious morbidity and mortality from influenza, therefore it is important to understand the safety and immunogenicity of influenza vaccination among them. Methods: This multicenter cohort study evaluated the immunogenicity and reactogenicity of an inactivated, monovalent, non-adjuvanted pandemic (H1N1) 2009 vaccine among the elderly, HIV-infected, rheumatoid arthritis (RA), cancer, kidney transplant, and juvenile idiopathic arthritis (JIA) patients. Participants were included during routine clinical visits, and vaccinated according to conventional influenza vaccination schedules. Antibody response was measured by the hemagglutination-inhibition assay, before and 21 days after vaccination. Results: 319 patients with cancer, 260 with RA, 256 HIV-infected, 149 elderly individuals, 85 kidney transplant recipients, and 83 with JIA were included. The proportions of seroprotection, seroconversion, and the geometric mean titer ratios postvaccination were, respectively: 37.6%, 31.8%, and 3.2 among kidney transplant recipients, 61.5%, 53.1%, and 7.5 among RA patients, 63.1%, 55.7%, and 5.7 among the elderly, 59.0%, 54.7%, and 5.9 among HIV-infected patients, 52.4%, 49.2%, and 5.3 among cancer patients, 85.5%, 78.3%, and 16.5 among JIA patients. The vaccine was well tolerated, with no reported severe adverse events. Conclusions: The vaccine was safe among all groups, with an acceptable immunogenicity among the elderly and JIA patients, however new vaccination strategies should be explored to improve the immune response of immunocompromised adult patients.
dc.description.indexMEDLINE
dc.description.sponsorshipFundacao Butantan
dc.identifier.citationPLOS ONE, v.6, n.11, article ID e27214, 7p, 2011
dc.identifier.doi10.1371/journal.pone.0027214
dc.identifier.issn1932-6203
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/22876
dc.language.isoeng
dc.publisherPUBLIC LIBRARY SCIENCE
dc.relation.ispartofPlos One
dc.rightsopenAccess
dc.rights.holderCopyright PUBLIC LIBRARY SCIENCE
dc.subject.otherrheumatic-diseases
dc.subject.otherinfection
dc.subject.otherarthritis
dc.subject.otherclassification
dc.subject.otherchildren
dc.subject.wosMultidisciplinary Sciences
dc.titleImmunogenicity and Reactogenicity of 2009 Influenza A (H1N1) Inactivated Monovalent Non-Adjuvanted Vaccine in Elderly and Immunocompromised Patients
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalMIRAGLIA, Joao L.:Butantan Inst, Clin Trials Div, Sao Paulo, Brazil
hcfmusp.author.externalVISO, Ana T. R.:Ctr Referencia & Treinamento DST AIDS CRT DST AID, Sao Paulo, Brazil
hcfmusp.author.externalTAYRA, Angela:Ctr Referencia & Treinamento DST AIDS CRT DST AID, Sao Paulo, Brazil
hcfmusp.author.externalTIMENETSKY, Maria do Carmo S. T.:Adolfo Lutz Inst, Sao Paulo, Brazil
hcfmusp.author.externalCARDOSO, Maria Regina A.:Univ Sao Paulo, Dept Epidemiol, Fac Saude Publ, Sao Paulo, Brazil
hcfmusp.author.externalGUEDES, Jose da S.:Butantan Inst, Clin Trials Div, Sao Paulo, Brazil
hcfmusp.author.externalRAW, Isaias:Butantan Inst, Clin Trials Div, Sao Paulo, Brazil
hcfmusp.author.externalKALIL, Jorge:Butantan Inst, Clin Trials Div, Sao Paulo, Brazil
hcfmusp.citation.scopus37
hcfmusp.contributor.author-fmusphcEDSON ABDALA
hcfmusp.contributor.author-fmusphcPAULO MARCELO GEHM HOFF
hcfmusp.contributor.author-fmusphcANDRE MACHADO LUIZ
hcfmusp.contributor.author-fmusphcDANISE SENNA OLIVEIRA
hcfmusp.contributor.author-fmusphcCARLA GONCALVES SCHAHIN SAAD
hcfmusp.contributor.author-fmusphcIEDA MARIA MAGALHAES LAURINDO
hcfmusp.contributor.author-fmusphcLIGIA CAMERA PIERROTTI
hcfmusp.contributor.author-fmusphcLUIZ SERGIO FONSECA DE AZEVEDO
hcfmusp.contributor.author-fmusphcLUCIA MARIA MATTEI DE ARRUDA CAMPOS
hcfmusp.contributor.author-fmusphcNADIA EMI AIKAWA
hcfmusp.contributor.author-fmusphcEXPEDITO JOSE DE ALBUQUERQUE LUNA
hcfmusp.contributor.author-fmusphcALEXANDER ROBERTO PRECIOSO
hcfmusp.description.articlenumbere27214
hcfmusp.description.issue11
hcfmusp.description.volume6
hcfmusp.origemWOS
hcfmusp.origem.pubmed22087267
hcfmusp.origem.scopus2-s2.0-80555145202
hcfmusp.origem.wosWOS:000297349700019
hcfmusp.publisher.citySAN FRANCISCO
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceTebas P, 2010, AIDS, V24, P2187, DOI 10.1097/QAD.0b013e32833c6d5c
hcfmusp.relation.referenceLiang XF, 2010, LANCET, V375, P56, DOI 10.1016/S0140-6736(09)62003-1
hcfmusp.relation.referenceZhu FC, 2009, NEW ENGL J MED, V361, P2414, DOI 10.1056/NEJMoa0908535
hcfmusp.relation.referenceCrum-Cianflone NF, 2011, CLIN INFECT DIS, V52, P138, DOI 10.1093/cid/ciq019
hcfmusp.relation.referencePetty RE, 2004, J RHEUMATOL, V31, P390
hcfmusp.relation.referenceHeinze G, 2002, STAT MED, V21, P2409, DOI 10.1002/sim.1047
hcfmusp.relation.referenceWHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934
hcfmusp.relation.referenceMiller E, 2010, LANCET, V375, P1100, DOI 10.1016/S0140-6736(09)62126-7
hcfmusp.relation.referenceSaad CGS, 2011, ANN RHEUM DIS, V70, P1068, DOI 10.1136/ard.2011.150250
hcfmusp.relation.referencePlennevaux E, 2010, LANCET, V375, P41, DOI 10.1016/S0140-6736(09)62026-2
hcfmusp.relation.referenceOgimi C, 2011, PEDIATR INFECT DIS J, V30, P208, DOI 10.1097/INF.0b013e3181f7ce44
hcfmusp.relation.referenceMcElhaney JE, 2011, AGEING RES REV, V10, P379, DOI 10.1016/j.arr.2010.10.008
hcfmusp.relation.reference[Anonymous], 2009, GLOB AL RESP WHO REC
hcfmusp.relation.referenceCoffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
hcfmusp.relation.referenceThompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333
hcfmusp.relation.referenceKunisaki KM, 2009, LANCET INFECT DIS, V9, P493, DOI 10.1016/S1473-3099(09)70175-6
hcfmusp.relation.referenceWeng HY, 2009, AM J EPIDEMIOL, V169, P1182, DOI 10.1093/aje/kwp035
hcfmusp.relation.referenceARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302
hcfmusp.relation.referenceBaguelin M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017074
hcfmusp.relation.referenceCenters for Disease Control and Prevention (CDC), 2009, MMWR-MORBID MORTAL W, V58, P467
hcfmusp.relation.reference*EMA, 1996, EUR MED AG PUBL
hcfmusp.relation.referenceEMA. Committee for Proprietary Medicinal Products (CPMP), 2004, CPMPVEG471703 EMA EU
hcfmusp.relation.referenceHOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767
hcfmusp.relation.referenceHuber PJ, 1967, P 5 BERK S MATH STAT, P221, DOI 10.3238/ARZTEBL.2011.0523A
hcfmusp.relation.referenceICH, 1996, INT C HARM TECHN REQ
hcfmusp.relation.referenceKanakoudi-Tsakalidou F, 2001, CLIN EXP RHEUMATOL, V19, P589
hcfmusp.relation.referenceKendal AP, 1982, CONCEPTS PROCEDURES, pB17
hcfmusp.relation.referenceMALLESON PN, 1993, J RHEUMATOL, V20, P1769
hcfmusp.relation.reference*MS, 2010, BAL PARC VAC GRIP A
hcfmusp.relation.reference*MS SVS DVE PNI, 2010, ESTR NAC VAC VIR INF
hcfmusp.relation.referencePlennevaux E, 2011, VACCINE, V29, P1569, DOI 10.1016/j.vaccine.2010.12.116
hcfmusp.relation.referenceUSFDA. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research, 2007, GUID IND CLIN DAT NE
hcfmusp.relation.referenceWHO, 2005, WKLY EPIDEMIOL REC, V80, P277
hcfmusp.relation.referenceWHO, 2009, WKLY EPIDEMIOL REC, V84, P249
hcfmusp.relation.referenceYanagisawa N, 2011, VACCINE, V29, P5694, DOI 10.1016/j.vaccine.2011.06.003
hcfmusp.scopus.lastupdate2024-05-18
relation.isAuthorOfPublication8f2a0908-530e-4109-9a31-d275670247f7
relation.isAuthorOfPublication706efa42-09fc-4065-8330-9391f2cbe840
relation.isAuthorOfPublication545bb43e-760d-423e-9019-829e06dd5e3f
relation.isAuthorOfPublication3168ad25-1082-4f8a-b3d7-64939a94cfb2
relation.isAuthorOfPublication6570ffde-4920-4e73-a1cd-4d146affef63
relation.isAuthorOfPublication4d108a13-19ca-4ef0-a9f0-d0becf3f7f69
relation.isAuthorOfPublicationedd4167d-0bc8-4227-a85a-577e4a8c6d04
relation.isAuthorOfPublicationfb62de7a-663d-48da-83b4-785c7e577fe5
relation.isAuthorOfPublication56623da9-adae-4ac2-99f9-75fd739393a9
relation.isAuthorOfPublicationd269a535-0477-491e-84b5-73ed38da4033
relation.isAuthorOfPublication68ca9ace-34dc-4608-8ffa-b42f5278e34e
relation.isAuthorOfPublication3ab91d24-eed0-4976-951f-f2eed2d03a9a
relation.isAuthorOfPublication.latestForDiscovery8f2a0908-530e-4109-9a31-d275670247f7
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_MIRAGLIA_Immunogenicity_and_Reactogenicity_of_2009_Influenza_A_H1N1_2011.PDF
Tamanho:
163.61 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/24
Carregar mais